Abstract
Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Keywords: Zolpidem, driving, accidents, compliance
Current Drug Safety
Title: Zolpidem and Traffic Safety - The Importance of Treatment Compliance
Volume: 2 Issue: 3
Author(s): Joris C. Verster, Edmund R. Volkerts, Berend Olivier, William Johnson and Laura Liddicoat
Affiliation:
Keywords: Zolpidem, driving, accidents, compliance
Abstract: Zolpidem is among the most frequently prescribed hypnotic drugs for those who suffer from insomnia. Recent media reports drew attention to driving impairment after zolpidem misuse. This review summarizes the available data on the effects of recommended use and misuse of zolpidem on driving ability and traffic safety. Both experimental studies and roadside evidence were taken into account. From these studies it must be concluded that patients should fully comply with the prescription instructions of zolpidem, i.e. to take the medication just prior to a full 8 hours of uninterrupted sleep. If this strategy is adopted, zolpidem is a safe alternative to benzodiazpine hypnotics and zopiclone who do show significant driving impairment the morning following bedtime administration. However, to ensure traffic safety higher dosages than recommended (10 mg) or allowing less than 8 hours between zolpidem intake and actual operation of a motor vehicle should be avoided.
Export Options
About this article
Cite this article as:
Verster C. Joris, Volkerts R. Edmund, Olivier Berend, Johnson William and Liddicoat Laura, Zolpidem and Traffic Safety - The Importance of Treatment Compliance, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668882
DOI https://dx.doi.org/10.2174/157488607781668882 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry Alkaloids: An Emerging Antibacterial Modality Against Methicillin Resistant Staphylococcus aureus
Current Pharmaceutical Design Statin Drugs, Metabolic Pathways, and Asthma: A Therapeutic Opportunity Needing Further Research
Drug Metabolism Letters Biomarkers in the Management of Difficult Asthma
Current Topics in Medicinal Chemistry Preface
Current Pharmaceutical Design CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Mood Charting and Technology: New Approach to Monitoring Patients with Mood Disorders
Current Psychiatry Reviews Radiation-Induced Pulmonary Epithelial-Mesenchymal Transition: A Review on Targeting Molecular Pathways and Mediators
Current Drug Targets Non-Peptidic Inhibitors of Cysteine Proteases
Mini-Reviews in Medicinal Chemistry Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry The Therapeutic Properties of Carapa guianensis
Current Pharmaceutical Design Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy
Current Pharmaceutical Design COVID-19 Treatment Success After Repeat Courses of Azithromycin: A Report of Three Cases
Infectious Disorders - Drug Targets Should Serology be Abolished in Favor of PCR for the Diagnosis of Mycoplasma pneumoniae Infections?
Current Pediatric Reviews Sleep Disturbances Due to Pulmonary Medications
Current Respiratory Medicine Reviews